Is Beigene a Chinese Company?

Yes, Beigene is a Chinese company. Beigene, Ltd. is dedicated to the discovery, creation, manufacturing, and distribution of novel pharmaceuticals. Co-founders of BeiGene, a fully comprehensive biotechnology company, are American entrepreneur John Oyler and Dr. Xiaodong Wang, the director of China’s National Institute of Biological Sciences (NIBS) in Beijing who is also one of the youngest members of the U.S. Academy of Science ever. The two set out to create a distinctive business that was first focused on the world market. BeiGene concentrates on creating cutting-edge cancer treatments where there is an untapped market worldwide.


Beigene Company Details

Headquarters Beijing, China
Industry Biotechnology and Pharmaceutical
Founded 2010
Founders John Oyler
Key Services Biopharmaceuticals, Oncology Research, Drug Development
Global Presence BeiGene operates globally with offices in multiple countries
Market Focus Specializes in developing cancer treatments and therapies
Notable Products Tislelizumab, Pamiparib, Zanubrutinib
Innovation Known for advancements in cancer treatment research
Employee Base Has a growing workforce with professionals worldwide
Stock Exchange BeiGene is publicly traded on the NASDAQ stock exchange under the ticker symbol “BGNE”


Xiaodong Wang, a Chinese-American scientist, and John V. Oyler, an American entrepreneur who currently serves as the company’s chairman as well as chief executive officer, created BeiGene in late 2010. Wang and Oyler planned a biopharmaceutical company that would conduct research and development in China and then concentrate on cancer treatment.

Beigene services/operations

Asia, Europe, Australia, Latin America, as well as North America are all home to BeiGene’s offices as well as operations. The company’s headquarters are located in Cambridge, Massachusetts, Beijing, and Basel.

With more than 10,000 workers worldwide, BeiGene has a market valuation of over $23 billion. With operations in Latin America, Asia, Europe, Australia, and North America, BeiGene is a worldwide player with a developing portfolio of cancer medicines at different phases of development.

What is Beigene known for?

BeiGene boasts one of the biggest oncology research teams globally, along with a wide and comprehensive pipeline that may potentially address 80% of cancer cases worldwide by type. In over 65 markets worldwide, BeiGene’s small molecule inhibitor of Bruton’s tyrosine kinase (BTK), BRUKINSA, is authorized for the treatment of different B-cell malignancies.

Tislelizumab, a humanized monoclonal antibody directed against the immune checkpoint receptor PD-1, constitutes one of the company’s most cutting-edge investigational drugs. It is presently being studied as a monotherapy as well as in combination with other therapies for different solid tumors as well as hematologic malignancies.

To develop and market cancer medicines, BeiGene is also well-known for working with biopharmaceutical companies such as Novartis, Bristol Myers Squibb for Celgene, and Amgen. Bruton’s tyrosine kinase inhibitor zanubrutinib and checkpoint inhibitor tislelizumab are among the medications that BeiGene has produced.


Global biotechnology leader BeiGene is renowned for finding and creating cutting-edge cancer treatments that are accessible and inexpensive for a far larger number of people globally.

Leave a Reply

Your email address will not be published. Required fields are marked *